
ExpreS²ion's core platform patent allowed in India

Hørsholm, Denmark, December 28, 2017 – Today, ExpreS²ion Biotech Holding AB and its affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") announce that the company's patent application "Improved Protein Expression System", that covers the entire ExpreS² platform, has been allowed in India and will be granted with expiry June 12, 2029.

"Obtaining a strong patent protection in India, one of the world's largest markets for vaccine technology, is an important step towards our goal to have the ExpreS² platform protected in all major markets and consolidate our position as a global player. We are now close to reaching this goal," says Steen Klysner, CEO of ExpreS²ion.

The patent application "Improved Protein Expression System" has been filed in 15 different countries covering the company's major markets. The patent has been issued in the United States, South Korea, Japan, Australia and China, and validated in several EU countries following approval by the European Patent Office.

Certified Adviser

Sedermora Fondkommission is appointed as Certified Adviser for ExpreS²ion.

For further information about ExpreS²ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS²ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on December 28, 2017.

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion's unique proprietary platform technology, ExpreS², is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS²ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.